SAN DIEGO, July 21, 2015 /PRNewswire/ -- Dauntless Pharmaceuticals, Inc. (Dauntless), a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC (Aegis) today announced a licensing agreement providing Dauntless’ access to Aegis’ Intravail® drug delivery technology for an undisclosed oncology application and an option for three additional drugs. Financial terms were not disclosed.
Joel F. Martin, President and CEO of Dauntless commented, “We are fortunate to be able to access Aegis’ proprietary Intravail® drug delivery technologies for an application that will benefit cancer patients. We have the option of licensing the Intravail® technology for additional drugs and are looking at a number of exciting opportunities.”
Edward T. Maggio, Chief Executive Officer of Aegis added, “The team at Dauntless has a track record of rapid, cost-effective clinical development and we are delighted to work with them on this new venture. Dauntless has several innovative ideas to develop additional drugs formulated with Intravail® and we are excited by the prospects of expanding the portfolio.”
About Dauntless Pharmaceuticals, Inc.
Dauntless Pharmaceuticals is a company founded by Sofinnova Ventures that manages the development of multiple clinical assets, using a separate corporation for each. This enables the optimal structuring of financial, human, and development resources as well as acquisitions and partnerships. Dauntless’ approach reduces fixed costs while leveraging project-specific human capital and external service providers. Dauntless has access to broad industry expertise and sources of capital that can speed the development of new specialty products to the benefit of entrepreneurs and inventors. For more information about Dauntless, please visit the Dauntless website at: www.dauntlessph.com
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our patented Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide, and non-peptide macromolecular and small molecule therapeutics via the intranasal administration route with exceptionally high and unmatched bioavailability that can currently only be achieved by injection. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our patented ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs. For more information about Aegis, please visit the Aegis website at: www.aegisthera.com
Contact for Further Information:
Corporate Inquiries:
Joel Martin, PhD
President and CEO
Dauntless Pharmaceuticals, Inc.
contact@dauntlessph.com
Ralph Barry
Chief Business Officer
Aegis Therapeutics, LLC
rbarry@aegisthera.com
Media Inquiries:
Jennifer James
Partner, Sofinnova
jennifer@sofinnova.com
(650) 681-8429
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dauntless-pharmaceuticals-and-aegis-therapeutics-announce-licensing-agreement-300115862.html
SOURCE Dauntless Pharmaceuticals
Help employers find you! Check out all the jobs and post your resume.
